Two studies indicate that higher doses of psilocybin are necessary for sustained reductions in depression and anxiety.
Comments from Matthew Johnson of Johns Hopkins provide an update on this research.
Three clinical trials are underway to find out if these psychedelic compounds can provide relief for patients.
Psychedelic Science Review Editor Barb Bauer conducts a review of some landmark studies.
“In the pharmaceutical drug development community, this is what you dream about.”
After 4.5 years, 60-80% of the study participants with life-threatening cancer still experienced significantly decreased anxiety or antidepressant effects.
Eleusis’s Phase I Alzheimer’s Trial Finds Favorable Safety & Tolerability of LSD in Older Volunteers
There were no abnormalities or deviations in safety or cognitive outcome measures compared to the baseline data.
Placebo-Controlled Study Finds Psilocybin Formulation is Safe and Well-Tolerated in Healthy Volunteers
The study used an investigational psilocybin formulation called COMP360 developed and produced by COMPASS Pathways.
The study will examine the effects of microdosing LSD on the everyday lives of the participants.
Usona Follows COMPASS in Receiving Breakthrough Therapy Designation for Psilocybin to Treat Depression
This means the FDA will work to expedite the development and review of psilocybin so it can get to patients with major depressive disorder as soon as possible.